Health Trials

Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)

3

Review clinical trials related to Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: Jul 13, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Read more
Status: Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.

Participants needed: 90
Trial details
Phase: Phase 3Age: 4-18Biological sex: MaleType: InterventionalSponsor: Dyne TherapeuticsUpdated: May 27, 2026Locations: 1
Eligibility criteria

Ambulatory male with confirmed diagnosis of DMD and with a mutation in the dystr... [+2]

Receipt of ongoing immunosuppressive therapy (other than glucocorticoids) within... [+6]

Read more
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 14, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Read more